Legal Representation
Attorney
Jeffrey H. Handelsman
USPTO Deadlines
Next Deadline
899 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20220607)
Due Date
June 07, 2028
Grace Period Ends
December 07, 2028
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
28 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jun 7, 2022 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Jun 7, 2022 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Mar 22, 2022 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Mar 22, 2022 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Mar 2, 2022 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Feb 17, 2022 | FIXD | O | ELECTRONIC RECORD REVIEW COMPLETE | Loading... |
| Sep 10, 2021 | ERRR | O | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | Loading... |
| Sep 8, 2021 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Sep 7, 2021 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Sep 7, 2021 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Sep 7, 2021 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Mar 5, 2021 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Mar 5, 2021 | GNRT | O | NON-FINAL ACTION E-MAILED | Loading... |
| Mar 5, 2021 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Mar 4, 2021 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Mar 4, 2021 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Mar 2, 2021 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Dec 2, 2020 | ERSI | I | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | Loading... |
| Nov 21, 2020 | GNS2 | O | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | Loading... |
| Nov 21, 2020 | GNSI | S | INQUIRY TO SUSPENSION E-MAILED | Loading... |
| Nov 21, 2020 | CNSI | R | SUSPENSION INQUIRY WRITTEN | Loading... |
| May 21, 2020 | GNS3 | O | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | Loading... |
| May 21, 2020 | GNSL | F | LETTER OF SUSPENSION E-MAILED | Loading... |
| May 21, 2020 | CNSL | R | SUSPENSION LETTER WRITTEN | Loading... |
| May 21, 2020 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Mar 10, 2020 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Mar 9, 2020 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Mar 6, 2020 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for use in treating dermatology, gastroenterology, rheumatology, and psychiatric disorders; Pharmaceutical preparations for use in the treatment of pain and inflammation; Pharmaceutical preparations directed to women's health for use in the treatment, alleviation and prevention of thermoregulatory dysfunctions and vasomotor symptoms including hot flashes, hot flushes, night awakenings, night sweats, and such disorders and conditions associated with perimenopause, menopause and hormonal deficiencies; Menstrual symptom treatment preparations; Pharmaceutical preparations for use in treating nephrology, neurology, oncology, urology, andrology and cardiology diseases and disorders, and for use in the treatment of nasal allergies, respiratory allergies, and for use as anti-infectives; contraceptive preparations; dietary and nutritional supplements; prenatal vitamins; pharmaceutical preparations for the treatment of bone diseases; preparations for the suppression of hormones; pharmaceutical preparations directed to women's health for use in the treatment, alleviation and prevention of overactive bladder, female sexual dysfunction, infertility, endometriosis, vaginitis, osteoporosis, osteopenia, pelvic pain, dyspareunia, and candidiasis; Diagnostic agents, preparations and substances for medical purposes; all of the aforesaid goods not for use as a product name of a pharmaceutical product
Additional Information
Design Mark
The mark consists of the stylized wording "SEBELA" in turquoise above the word "PHARMACEUTICALS" in grey, appearing to the right of a stylized reverse letter "S" with a horizontal line and three dots all in grey.
Color Claim
The color(s) grey and turquoise is/are claimed as a feature of the mark.
Classification
International Classes
005